Biological therapies for psoriasis have high efficacy and comprise three main targeting categories: TNF inhibitors, interleukin-12 (IL-12) and IL-23 inhibitors, and IL-17 inhibitors.44 This evidence concerns the gene IL17A and psoriasis.